The 340B PATIENTS Act of 2024

This bill clarifies that drug manufacturers must offer 340B discounted pricing for covered outpatient drugs regardless of where or how the drugs are dispensed - specifically including arrangements where covered entities (like community health centers, clinics, and hospitals) contract with pharmacies to dispense 340B drugs to patients. It explicitly prohibits manufacturers from imposing conditions on these arrangements, such as restricting delivery locations or requiring additional data. The bill also establishes civil penalties of up to $2 million per day for manufacturers violating these rules, with penalties assessed by the Secretary of Health and Human Services. This directly affects covered entities that rely on contract pharmacies to access specialty drugs for patients with conditions like cancer or multiple sclerosis, ensuring they can stretch scarce resources to provide comprehensive care.